IRIX IRIX
Company Profile ↓Company Overview
IRIX (IRIX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Jan 2026 Revenue of $52.67M (+8.2% YoY); net profit $-4.44M.
- Trailing 12 Months Year-on-year growth — revenue +8.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.36% |
| 1 Year: | 8.23% |
Stock Price Performance
| 1 Year: | -36.05% |
| 6 Months: | -40.56% |
| 3 Months: | -19.61% |
| 1 Month: | -24.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)25.93 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 45.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Apr 2015 | Jul 2015 | Oct 2015 | Apr 2016 | Jul 2016 | Oct 2016 | Dec 2016 | Apr 2017 | Jul 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.87M | - | 9.51M | 10.30M | 11.32M | 10.60M | 10.43M | 10.66M | 9.02M | 6.22M | 8.80M | 11.96M | 13.43M | 13.26M | 13.39M | 13.76M | 14.63M | 13.71M | 12.86M | 12.85M | 11.76M | 12.63M | 11.58M | 11.90M | 13.57M | 12.48M | 11.80M |
| Gross Profit | 4.72M | 5.05M | 5.30M | 5.15M | 5.41M | 4.22M | 4.84M | 5.30M | 5.73M | 4.25M | 5.56M | 4.46M | 4.50M | 4.37M | 2.17M | 3.92M | 4.27M | 4.58M | 4.26M | 4.55M | 4.28M | 3.92M | 2.41M | 3.65M | 4.94M | 6.11M | 5.78M | 5.98M | 6.27M | 6.46M | 5.94M | 5.36M | 5.62M | 4.46M | 5.13M | 4.32M | 5.05M | 4.68M | 4.01M | 4.74M |
| Operating Income | 665.00K | 597.00K | 400.00K | 606.00K | 403.00K | -747.00K | 143.00K | 152.00K | -394.00K | -1.25M | -1.08M | -1.86M | -2.74M | -3.07M | -5.22M | -3.62M | -3.28M | -3.06M | -3.04M | -2.47M | -1.85M | -1.65M | -2.78M | -1.85M | -1.84M | -1.14M | -2.16M | -2.28M | -2.16M | -1.70M | -2.34M | -2.89M | -1.69M | -3.29M | -2.64M | -1.87M | -205.00K | -940.00K | -1.41M | -324.00K |
| Net Income | 530.00K | 487.00K | 297.00K | 490.00K | 246.00K | -652.00K | 442.00K | 101.00K | -328.00K | -671.00K | -10.81M | -1.87M | -2.75M | -3.10M | -5.16M | -3.60M | -3.28M | -3.07M | -3.05M | -2.42M | -1.78M | -1.65M | -2.78M | -1.72M | -2.01M | 1.39M | -2.17M | -2.39M | -2.24M | -1.77M | -2.09M | -2.77M | -1.75M | -3.46M | -2.68M | -1.93M | -1.69M | -994.00K | -1.57M | -524.00K |
| Diluted EPS | 0.05 | 0.05 | 0.03 | 0.05 | 0.02 | -0.07 | 0.04 | 0.01 | -0.03 | -0.07 | -1.04 | -0.16 | -0.24 | -0.27 | -0.44 | -0.31 | -0.28 | -0.26 | -0.22 | -0.18 | -0.13 | -0.12 | -0.20 | -0.12 | -0.14 | 0.09 | -0.14 | -0.15 | -0.14 | -0.11 | -0.13 | -0.17 | -0.11 | -0.21 | -0.16 | -0.12 | -0.10 | -0.06 | -0.09 | -0.03 |
| R&D Expense | 923.00K | 1.19M | 1.31M | 1.10M | 1.28M | 1.48M | 1.24M | 1.36M | 1.39M | 1.26M | 1.36M | 1.34M | 1.37M | 1.32M | 1.28M | 1.10M | 901.00K | 1.15M | 958.00K | 929.00K | 1.01M | 719.00K | 807.00K | 869.00K | 1.17M | 1.67M | 1.79M | 2.12M | 1.92M | 1.69M | 1.75M | 1.84M | 1.54M | 1.54M | 1.50M | 1.30M | 876.00K | 871.00K | 972.00K | 905.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.03M | 32.31M | 33.16M | 33.86M | 38.27M | 42.81M | 41.76M | 46.16M | 41.59M | 42.60M | 43.45M | 36.35M | 53.90M | 56.97M | 51.87M | 48.67M | 52.67M |
| Gross Profit | 15.44M | 16.20M | 16.29M | 16.35M | 18.59M | 21.41M | 19.95M | 20.84M | 15.50M | 17.47M | 17.94M | 15.56M | 22.83M | 25.37M | 21.81M | 19.50M | 19.23M |
| Operating Income | 1.23M | 1.19M | 1.93M | -860.00K | 2.63M | 2.59M | 288.00K | -2.56M | -12.89M | -12.87M | -8.97M | -6.58M | -7.53M | -7.54M | -10.01M | -8.30M | -2.57M |
| Net Income | 2.58M | 3.05M | 2.61M | 1.44M | 2.23M | 10.04M | 474.00K | -11.71M | -12.87M | -12.81M | -8.81M | -6.33M | -5.22M | -7.55M | -9.57M | -8.91M | -4.44M |
| Diluted EPS | - | 0.30 | 0.26 | 0.16 | 0.22 | 0.97 | 0.05 | -1.15 | -1.11 | -1.05 | -0.64 | -0.46 | -0.34 | -0.47 | -0.59 | -0.54 | -0.26 |
| R&D Expense | 3.31M | 3.75M | 3.91M | 4.38M | 3.68M | 4.63M | 5.21M | 5.37M | 5.21M | 4.01M | 3.68M | 3.28M | 6.87M | 7.17M | 6.83M | 5.45M | 3.67M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2009 | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 29.22M | 32.15M | 28.91M | 33.68M | 41.82M | 41.82M | 48.14M | 41.65M | 41.67M | 34.81M | 27.97M | 48.69M | 42.29M | 34.44M | 29.14M | 29.15M |
| Total Equity | 11.75M | 15.03M | 19.43M | 22.43M | 21.91M | 25.85M | 33.74M | 33.69M | 39.16M | 30.52M | 29.96M | 22.70M | 17.37M | 23.30M | 17.23M | 9.52M | 2.10M | 4.92M |
| Cash & Equivalents | 4.48M | 8.37M | 8.35M | 10.79M | 11.90M | 13.44M | 13.30M | 9.99M | 23.75M | 21.71M | 21.19M | 12.65M | 11.63M | 23.85M | 13.92M | 7.03M | 2.39M | 6.03M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | 1.25M | - | - | - | 1.00M | - |
| Total Liabilities | - | - | 9.79M | 9.72M | 7.01M | 7.82M | 8.08M | 8.13M | 8.98M | 11.12M | 11.71M | 12.11M | 10.60M | 25.39M | 25.06M | 24.91M | 27.04M | 24.23M |
| Current Liabilities | - | - | 9.20M | 8.91M | 6.37M | 7.36M | 7.04M | 7.43M | 8.17M | 10.39M | 10.50M | 9.78M | 8.68M | 12.65M | 12.45M | 12.97M | 16.56M | 13.21M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 3.01M | 1.14M | 2.25M | -1.14M | 767.00K | 4.01M | -593.00K | - | -3.56M | -10.03M | -7.91M | -3.24M | 8.22M | -9.52M | -6.75M | -7.29M | -2.12M |
| Investing Cash Flow | -190.00K | -418.00K | -278.00K | -722.00K | -763.00K | -1.03M | -1.30M | - | -782.00K | -827.00K | -509.00K | -93.00K | -5.56M | -286.00K | -109.00K | -13.00K | -143.00K |
| Financing Cash Flow | -1.66M | -2.27M | -327.00K | -2.39M | 1.03M | -3.13M | -1.42M | - | 2.31M | 10.38M | -156.00K | 2.47M | 9.47M | -73.00K | -5.00K | 2.60M | 5.96M |
| Capital Expenditure | -190.00K | -193.00K | -203.00K | -394.00K | -380.00K | -568.00K | -875.00K | -1.06M | -575.00K | -440.00K | -128.00K | -97.00K | -213.00K | -286.00K | -109.00K | -13.00K | -143.00K |
| Free Cash Flow | 2.82M | 943.00K | 2.05M | -1.53M | 387.00K | 3.45M | -1.47M | - | -4.14M | -10.46M | -8.04M | -3.33M | 8.00M | -9.80M | -6.85M | -7.30M | -2.26M |
| Share Buybacks | 0 | 0 | 648.00K | 2.83M | 426.00K | 4.67M | 1.56M | 59.00K | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 49.8% | 50.1% | 49.1% | 48.3% | 48.6% | 50.0% | 47.8% | 45.1% | 37.3% | 41.0% | 41.3% | 42.8% | 42.4% | 44.5% | 42.0% | 40.1% | 36.5% |
| Operating Margin % | 4.0% | 3.7% | 5.8% | -2.5% | 6.9% | 6.0% | 0.7% | -5.6% | -31.0% | -30.2% | -20.7% | -18.1% | -14.0% | -13.2% | -19.3% | -17.1% | -4.9% |
| Net Margin % | 8.3% | 9.4% | 7.9% | 4.2% | 5.8% | 23.4% | 1.1% | -25.4% | -30.9% | -30.1% | -20.3% | -17.4% | -9.7% | -13.2% | -18.5% | -18.3% | -8.4% |
| ROE % | 17.2% | 15.7% | 11.6% | 6.6% | 8.6% | 29.8% | 1.4% | -29.9% | -42.2% | -42.8% | -38.8% | -36.4% | -22.4% | -43.8% | -100.5% | -424.9% | -90.1% |
| ROCE % | - | 5.9% | 8.3% | -3.8% | 10.0% | 7.4% | 0.8% | -6.4% | -41.2% | -41.3% | -35.8% | -34.1% | -20.9% | -25.3% | -46.6% | -66.0% | -16.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IRIX
Iridex schedules Q2 business update after Aug. 18 close - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPRVhjdF9vMHlYNW44dVFLT2d1M3RtaHkwd2cxYTJqQ0VjUGVxdFh6eWlSakdaMFNjZjg1WTViWGtOU3RmNXNLMHRZNmFDN0N2XzNnTkJudUF0bTdaWERfeTBkTml3MjNZcWZQMjE5dnVzLVJaU3RhaGZlMUgtUkgyYVc4NXF4WUF6dHlrWn…
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPQVZvZG1fYkR5Mk5OcUVIZWJGbHNpU0NqRnZ3OG93Szh3QVkxMHpRWXBwWFBac1ZWTlZNdEJpMndUc25FQnlReGdpWTZPdVRnVVFCOUxfUnhHTzN0bXVlSUdKRmJaejdZcDd4ZzVCR1pGcjlFUGx5QzVxYWdNU1NlQUpUVENzUHlFQU5mQU…
IRIX|IRIDEX Corp|Price:0.829|Chg%:+0.009 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9DZGd4UjVlZGpaX3VwWkZNa0VNVlFCamNmSGw3b1Jha1lNenRsRWdxRU1vMFBRMzB6RWNxeVBheHFXRmRHZW56QWl2VWo4d1k2OWE4eDRpRWxsMHlCRjN1SjYtb3k5X0E5bTNLYUZB?oc=5" target="_blank">IRIX|IRIDEX Corp|Pr…
Portfolio Update 315 (NASDAQ:IRIX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOWkpZTnE4VVIyOFJIZGFONGdmaWdON1RCOFFOaWc3ZkJLR1JnSUtETHNuMlhjQVJ4Nk5vcXAyd1pFNE9ZUnJGb1dLMG80OGtKbFZNMWxMMWR2c3Nsb1YwN21LY3dVZ1JfbU11bnlTMERkbVNGVW0wcUZiS1I1bHAya1A1cF94cXZLQmliSl…
More Than 4,300 EyeProGPO Members Gain Preferred EndoProbe Pricing - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQcHBFNUowd2NycVdlYU4xMGN0RGN1LVZOdDJjWDQ4aVd6NHFfTFBsaXpzLUZkV2Noc240TFh5bjdkRTUzcGR4Z200azFLdGJjR0cyYnZnd1RHemRtc0VHX2RqTlp4U2FIUlprWnR5T0Y3TWMxLW9sU0ItZmhXSDZXNFJMYWZVYS1IN2xmUl…
Iridex Reports First Quarter 2026 Financial Results - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSzNpc3dZb21WNG5sQ2ZjOWpxYnQ0eC13aW5mS3ctQnZ6Wl9UT3ViRlVydmRzNENQMnJ3dHQ5SkVCQ2liUnY3SG53UkF1RGZZSDhUeFVTUW5ZUjVvWHhnSE9HUC1LYUNoTTNRcC1tNUtHOUYyVndlYllRc09YczNWVzRCZzRRMGNtMEZGbW…
IRIX — Frequently Asked Questions
What is the current share price of IRIX?
As of 2026-08-05 17:25 PDT, IRIX trades at $0.84 on NASDAQ/NYSE. Its 52-week range is $0.82 to $1.56.
What is the P/E ratio of IRIX?
IRIX trades at a trailing price-to-earnings (P/E) ratio of -3.23.
What is the return on equity (ROE) of IRIX?
IRIX has a return on equity (ROE) of -90.15%. Its return on capital employed (ROCE) is -16.13%.
Is IRIX a good stock to buy?
This page provides a data-driven analysis of IRIX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.